2023年，当全球减肥药市场被GLP-1类药物点燃时，一款曾被称为“女性伟哥”的老药Bremelanotide（布美诺肽，Vyleesi）正悄然上演一场“科学变形记”。

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...

Co-administered bremelanotide + tirzepatide, bremelanotide alone, and tirzepatide alone arms showed improvement in appetite suppression, fullness, and satiety Bremelanotide matched or exceeded ...

In contrast, patients who transitioned to low-dose bremelanotide after initial weight loss on tirzepatide maintained their weight without any significant regain, underscoring the potential of MC4R ...

(New York Times) Participants on tirzepatide combined with the investigational MC4R agonist bremelanotide, as well as those on each of the two drugs alone, reported significant improvements in ...

We're excited with the results, which demonstrated that low-dose bremelanotide matched tirzepatide in appetite suppression, a compelling outcome," said Carl Spana, Ph.D., President and CEO of Palatin.